A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2009
At a glance
- Drugs Ritobegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 10 Sep 2009 Last checked against ClinicalTrials.gov record.
- 10 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2008 New trial record.